Pune Faces Fresh Scrutiny Over Drug Storage Standards
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of a Carry and Forwarding (C&F) facility operated by Cipla Pharma & Life Sciences at Wadki in Pune, following regulatory findings involving prescription-drug packaging, storage, inventory controls and recall procedures. The action, effective August 27, puts pharmaceutical distribution practices under sharper scrutiny at a time when reliable medicine supply depends as much on warehouse systems as manufacturing standards.
The case centres on Reactin Plus Tablets, classified as a Schedule H prescription medicine. During an inspection in June, the regulator found packaging carrying an unauthorised description of the product as an “analgesic and antipyretic”. The FDA subsequently seized stock valued at ₹11.19 lakh and ordered its withdrawal from the market, treating the packaging issue as misbranding under the applicable drug regulations. The regulatory concern extended beyond labelling. A subsequent inspection of the Pune C&F operation identified differences between physical inventory and computerised records, as well as inconsistencies involving purchase and sales documentation. Inspectors also reported medicines being kept directly on the floor, inadequate pallet and rack arrangements, and gaps in systems for recording and managing expired medicines. For Pune’s wider urban economy, the episode highlights an often-overlooked part of healthcare infrastructure: the distribution network between manufacturers, warehouses, pharmacies and patients. Pharmaceutical logistics requires controlled storage, traceable inventories and timely recalls. Weaknesses at any stage can make it harder to identify affected batches quickly and can increase operational risks for pharmacies and consumers.
The FDA also alleged that directions connected with the Reactin Plus recall were not fully followed. A show-cause process was subsequently undertaken, after which the regulator cancelled the relevant sale licences. The action signals that compliance is being assessed not only at the point of manufacture but across the systems through which medicines move into the market. Cipla Pharma & Life Sciences has contested the order and said the matter is under judicial consideration. The company has also stated that the regulatory order does not allege concerns regarding the safety, quality or efficacy of its products, nor does it indicate a patient-safety issue.
The immediate legal process will determine the next stage of the dispute. For regulators and the pharmaceutical sector, however, the broader issue is operational: drug distribution compliance requires accurate records, suitable storage and effective recall mechanisms. Strengthening these systems is essential to making urban healthcare supply chains more reliable and accountable.
